Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Full-thickness Macular Hole Formation and Spontaneous Closure Following Vitrectomy Surgery: A Case Report and Review of the Literature.

Journal of ophthalmic & vision research·2026

Same author

Photobiomodulation for Dry Age-related Macular Degeneration.

Ophthalmic surgery, lasers & imaging retina·2026

Same author

Clinical Decision Support in Retina Using Large Language Models and Vision-Language Models.

Ophthalmic surgery, lasers & imaging retina·2026

Same author

Time for "Cyanescence" to Become Cyanotic. It's ICG "Fluorescence".

Ophthalmic surgery, lasers & imaging retina·2025

Same author

Safety Assessment of Aqueous Humor Liquid Biopsy in Retinoblastoma: A Multicenter Study of 1203 Procedures.

Ophthalmology·2025

Same author

Adjuvant Brachytherapy Using Iodine-125 Plaques for Conjunctival Melanoma with Scleral Invasion.

Seminars in ophthalmology·2025

Search research articles

Related Experiment Video

Updated: Dec 27, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

MACULAR HOLE CLOSURE WITH TOPICAL STEROIDS.

Alyssa C Bonnell¹, Sofia Prenner^1,2, Max S Weinstein^1,2

¹Department of Ophthalmology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey; and.

Retinal Cases & Brief Reports

|March 6, 2020

Summary

Topical difluprednate 0.05% effectively closed full-thickness macular holes in four patients, improving visual acuity within 12 weeks. Some patients experienced increased intraocular pressure as a side effect.

More Related Videos

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy

Published on: January 22, 2018

Iris Fixation via External Pentagram Suturing

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

Related Experiment Videos

Last Updated: Dec 27, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy

Published on: January 22, 2018

Iris Fixation via External Pentagram Suturing

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

Area of Science:

Ophthalmology
Retinal Diseases
Pharmacological Treatments

Background:

Full-thickness macular holes can lead to significant vision loss.
Current treatments for macular holes have varying success rates and potential complications.

Purpose of the Study:

To evaluate the efficacy of topical difluprednate 0.05% in achieving closure of full-thickness macular holes.
To assess visual acuity outcomes and intraocular pressure changes associated with difluprednate treatment.

Main Methods:

Retrospective chart review of 4 patients with full-thickness macular holes.
Treatment involved topical difluprednate 0.05% drops administered four times daily for at least 12 weeks.
Outcomes assessed via optical coherence tomography, visual acuity measurements, and intraocular pressure monitoring.

Main Results:

Macular hole closure was achieved in all 4 patients within 12 weeks.
The average time to macular hole closure was 5 weeks.
Visual acuity improved from an average of 20/42 at baseline to 20/26 post-treatment.
Two patients experienced elevated intraocular pressure.

Conclusions:

Topical difluprednate 0.05% demonstrated effectiveness in promoting macular hole closure.
The treatment was associated with reduced macular edema and improved visual acuity.
Potential side effects include increased intraocular pressure, necessitating monitoring.